Objectives: Cardiovascular disease is one of the important cause of mortality among patients with Bipolar Disorder. Castelli Risk index I and II (CRI-I and II), Atherogenic Index of Plasma (AIP) and Atherogenic coefficient (AC) are new parameters in assessing cardiovascular risk. In this study we aimed to explore the status of cardiovascular risk factors and their alterations with treatment in manic episode.
Methods: Bipolar Disorder inpatients who were in manic episode and age-gender matched healthy controls were included in the study. CRI-I, CRI-II, AIP and AC parameters were calculated before and after treatment. The statistical significance level was accepted as p<0.05.
Results: Sixty-eight male patients and 60 healthy controls were included in the study. CRI-I, CRI-II, AIP and AC parameters showed an increase after treatment (p<0.001 for all parameters). There was no significant difference between patients and controls in terms of CRI-I and CRI-II and AC (p=0.129, p=0.573, p=0.129 respectively). Although mean AIP levels of patients was significantly lower than control group (p=0.031), the significance disappeared when we compared the patients and controls according to being in low, medium, and high risk groups (χ2=0.826, p=0.662).
Conclusions: Even in short term of treatment, antipsychotics have an important role in developing dyslipidemia and increasing cardiovascular risk. Manic state may have positive or at least no additional influences on atherogenic risk.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.dsx.2017.03.038 | DOI Listing |
Adv Ther
December 2024
Global Medical and Patient Affairs, Servier, Suresnes, France.
Introduction: The aim of the observational SIMPLE study was to assess real-life effectiveness and safety of a single-pill combination (SPC) of perindopril arginine/amlodipine in a broad range of subjects with newly diagnosed mild-to-moderate hypertension treated in Canadian general practice.
Methods: Treatment-naïve participants aged 18-65 years with mild-to-moderate hypertension, whose physicians decided to initiate the perindopril/amlodipine SPC, were recruited from Canadian clinical practice from October 2017 to February 2019. Participants were followed at 3- (M3) and 6-month (M6) visits after treatment initiation.
Diabetes Ther
December 2024
Patient Author, Heart Sistas, North Lauderdale, FL, USA.
Type 2 diabetes (T2D) frequently coexists with cardiorenal complications. Therefore, a holistic approach to patient management is required, with specialists such as primary care physicians, cardiologists, endocrinologists, and nephrologists working together to provide patient care. Although glycemic control is important in the management of T2D, patients with T2D and acceptable glycemic control are still at risk from cardiovascular (CV) events such as stroke, heart attack, and heart failure (HF).
View Article and Find Full Text PDFCardiovasc Drugs Ther
December 2024
Department of Cardiology, Qingdao University, Qingdao, Shandong, China.
JA Clin Rep
December 2024
Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Background: Local anesthetic systemic toxicity (LAST) is a rare but potentially life-threatening complication. Under general anesthesia, neurological signs are often masked, delaying diagnosis and increasing the risk of sudden cardiovascular collapse. Therefore, early detection methods are critically needed.
View Article and Find Full Text PDFAnn Hematol
December 2024
Department of Medical Oncology, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, Hebei, China.
The first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has recently undergone major changes, and targeted therapies have ushered in a new era of CLL/SLL treatment. Scientists in different countries have successively analyzed the efficacy of various drugs, but safety studies are relatively insufficient. Therefore, this systematic evaluation and retrospective meta-analysis was conducted to compare the differences in adverse effects and their incidence among first-line treatment regimens for CLL/SLL.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!